What You Ought to Know:
– BrightInsight, Inc., a supplier of regulated digital health options, has introduced an expanded multi-year partnership with Sanofi, a world biopharmaceutical firm. This expanded partnership builds on a profitable collaboration that started in 2022 when Sanofi chosen the BrightInsight Platform to speed up the event of a SaMD for one in every of its specialty care medicines.
– The objective of the collaboration goals to speed up Sanofi’s drug improvement timeline and enhance affected person outcomes by means of progressive digital well being options.
Accelerating Time-to-Marketplace for New Therapies
Sanofi goals to chop its drug improvement timeline in half, and this partnership with BrightInsight will play a key function in reaching that objective. By leveraging BrightInsight’s platform and expertise, Sanofi can streamline the event and deployment of digital well being options that help scientific trials, improve affected person engagement, and enhance treatment adherence.
Enhancing Affected person Expertise with “MyWay”
Below the expanded partnership, Sanofi will make the most of BrightInsight’s “MyWay” cell utility, a Software program as a Medical Machine (SaMD) answer designed to empower sufferers in managing their well being situations. MyWay gives a number of key options:
- Symptom Monitoring: Permits sufferers to trace their signs, akin to flares or illness development.
- Treatment Administration: Helps sufferers handle their drugs, together with monitoring injections and adherence.
- Monetary Monitoring: Permits sufferers to trace medical bills in choose international locations.
- Care Staff Communication: Facilitates direct communication with healthcare suppliers.
- Seamless Consumer Expertise: Gives a user-friendly and intuitive platform for managing well being.
“Sanofi is acknowledged globally for the transformational therapies that they develop and their impression on affected person lives, and BrightInsight is honored to function one in every of their digital companions to drive worth for these therapies,” stated Kal Patel, MD, CEO and Co-Founder, BrightInsight. “The robustness of our BrightInsight Platform and Illness Administration Answer allows Sanofi to rapidly launch and scale companion apps throughout completely different manufacturers and markets, configuring every answer to particular illness populations and market necessities in a quick, patient-centric, and compliant method globally.”
